Interferon alpha controlled-release - Hepasome Pharmaceuticals

Drug Profile

Interferon alpha controlled-release - Hepasome Pharmaceuticals

Alternative Names: Controlled-release IFN-alpha - Hepasome Pharmaceuticals; HDV-IFN; HDV-Interferon

Latest Information Update: 07 Aug 2015

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Hepasome Pharmaceuticals
  • Class Antineoplastics; Antivirals; Interferons
  • Mechanism of Action Interferon alpha stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • No development reported Hepatitis C

Most Recent Events

  • 07 Aug 2015 No development reported - Phase-II for Hepatitis C (Combination therapy, Treatment-experienced) in India (SC)
  • 07 Aug 2015 No recent reports on development identified - Phase-II for Hepatitis C (Combination therapy, Treatment-naive) in India (PO)
  • 31 May 2008 Phase-II clinical trials in Hepatitis C in India (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top